These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18940662)

  • 21. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
    Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Dietrich J; Hulme C; Hurley LH
    Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Affinity purification of protein kinases that adopt a specific inactive conformation.
    Ranjitkar P; Maly DJ
    Methods Mol Biol; 2012; 928():143-51. PubMed ID: 22956139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
    Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
    Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
    Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
    Lin YL; Meng Y; Huang L; Roux B
    J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H; Holyoake TL; Bhatia R
    Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
    von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
    Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
    Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
    Jacobs MD; Caron PR; Hare BJ
    Proteins; 2008 Mar; 70(4):1451-60. PubMed ID: 17910071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
    Mokhtari D; Al-Amin A; Turpaev K; Li T; Idevall-Hagren O; Li J; Wuttke A; Fred RG; Ravassard P; Scharfmann R; Tengholm A; Welsh N
    Diabetologia; 2013 Jun; 56(6):1327-38. PubMed ID: 23462796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
    Preyer M; Vigneri P; Wang JY
    PLoS One; 2011 Feb; 6(2):e17020. PubMed ID: 21347248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
    Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
    Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations.
    Pereira EG; Moreira MA; Caffarena ER
    J Mol Model; 2012 Sep; 18(9):4333-41. PubMed ID: 22570081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type.
    Wiwanitkit V
    Indian J Cancer; 2009; 46(4):335-6. PubMed ID: 19749465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
    Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
    BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.
    Salah E; Ugochukwu E; Barr AJ; von Delft F; Knapp S; Elkins JM
    J Med Chem; 2011 Apr; 54(7):2359-67. PubMed ID: 21417343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.